期刊文献+

Campath-1H对食蟹猴免疫细胞的清除作用和免疫重建研究 被引量:1

Campath-1H depletes lymphocytes in blood and lymphatic tissues of cynomolgus monkeys
下载PDF
导出
摘要 目的:研究免疫诱导剂Campath-1H对淋巴组织免疫细胞的清除和重建的时效性。方法:筛选雄性成年食蟹猴15只,随机分成五组,给予相同剂量的Campath-1H(3.0 mg/kg),测定Campath-1H的药物代谢参数,并分别在给药前、给药后3、9、14、21和35 d检测外周血、脾、淋巴结等免疫细胞的清除和重建规律。结果:Cam-path-1H对外周血淋巴细胞清除最显著,对单核细胞、NK细胞作用较小,对粒细胞没有清除作用。结论:Cam-path-1H对食蟹猴外周血各类免疫细胞清除效能不同,可能与细胞表面CD52抗原密度有关;对次级淋巴组织淋巴细胞的清除效能和抑制时间低于外周血。 Objective: To investigate the effect of Campath-1H induction therapy on lymphodepletion in cynomolgus monkeys.Methods: Fifteen screened cynomolgus monkeys were randomly enrolled into 5 groups(n=3),and each of them received a single injection of Campath-1H at the dose of 3.0 mg/kg.Monkeys were anesthesied at each scheduled timepoints,then peripheral blood and secondary lymphatic tissues were obtained for flow cytometric analysis and histological examination.Results: Campath-1H showed different depletional profiles on lymphocytes,monocytes,NK cells and granulocytes.In contrasting with peripheral blood,spleen and lymph node lymphocytes were relatively resistant to Campath-1H-induced depletion.Conclusion: Depletional efficiency of Campath-1H was determined by cell surface expression of CD52 antigen.And biopsy of lymph node is necessary and may be sufficient to assess lymphocytes clearance in secondary lymphoid organs in this model.
出处 《肠外与肠内营养》 CAS 北大核心 2011年第3期163-167,共5页 Parenteral & Enteral Nutrition
基金 国家科技支撑计划课题(2008BAI60B06) "973项目"(2009CB522405 2007CB513005) 江苏省科技攀登计划(BK2008034)
关键词 Campath-1H 免疫细胞清除 免疫重建 食蟹猴 Campath-1H Lymphodepletion Immune reconstitution Cynomolgus
  • 相关文献

参考文献16

  • 1Nishida S, Levi D, Kato T, et al. Ninety-five cases of intestiHal transplantation at the University of Miami. J Gastrointest Surg, 2002,6 ( 2 ) : 233-239.
  • 2Granl D, Abu EK, Reyes J, et al. 2003 report of the intestine transplant registry: a new era has dawned. Ann Surg, 2005,241 (4) :6074-613.
  • 3Nishida S, Levi DM, Moon Jl,et al. Intestinal transplantation with alemtuzumab( Campath-1H ) induction for adult patients. Transplant Proe,2006,38 ( 6 ) : 1747-1749.
  • 4Jilani I, Keating M, Giles FJ, et al. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res, 2004,28 ( 12 ) : 1255-1262.
  • 5Sehroder C, Azimzadeh AM, Wu G, et ah Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol,2003,12 ( 1 ) :19-28.
  • 6Demko S, Summers J, Keegan P, et al. FDA drug approval summary: alemluzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oneologist ,2008,13 ( 2 ) : 167-174.
  • 7Bakr MA. Induction therapy Exp Clin Transplant, 2005,3 ( 1 ) : 320-328.
  • 8Calne R, Friend P, Moffatt S,eI al. Prope tolerance, perioperative campalh lit, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet, 1998,351 ( 9117 ) : 1701 - 1702.
  • 9Calne RY. Prope tolerance with alemtuzumab. Liver Transpl, 2005,11 ( 3 ) :361-363.
  • 10Morris PJ, Russell NK. Alemtuzumab ( Campath-1H ) : a systematic review in organ transplantation. Transplantation, 2006,81 ( 10 ) : 1361-1367.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部